The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A10 | Drugs used in diabetes | |
| 3 | A10B | Blood glucose lowering drugs, excl. insulins | |
| 4 | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | |
| 5 | A10BK01 | Dapagliflozin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 10 mg |
| Active Ingredient | Description | |
|---|---|---|
| Dapagliflozin |
Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DUFORZIG Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
| FORXIGA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SAGALATIN Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
